263 related articles for article (PubMed ID: 22117499)
1. Emerging role of whole-body 18F-fluorodeoxyglucose positron emission tomography as a marker of disease activity in patients with sarcoidosis: a systematic review.
Treglia G; Taralli S; Giordano A
Sarcoidosis Vasc Diffuse Lung Dis; 2011 Oct; 28(2):87-94. PubMed ID: 22117499
[TBL] [Abstract][Full Text] [Related]
2. The role of 18F-FDG-PET and PET/CT in patients with sarcoidosis: an updated evidence-based review.
Treglia G; Annunziata S; Sobic-Saranovic D; Bertagna F; Caldarella C; Giovanella L
Acad Radiol; 2014 May; 21(5):675-84. PubMed ID: 24703482
[TBL] [Abstract][Full Text] [Related]
3. Comparative evaluation of 18F-FDG PET and 67Ga scintigraphy in patients with sarcoidosis.
Nishiyama Y; Yamamoto Y; Fukunaga K; Takinami H; Iwado Y; Satoh K; Ohkawa M
J Nucl Med; 2006 Oct; 47(10):1571-6. PubMed ID: 17015889
[TBL] [Abstract][Full Text] [Related]
4. Results of 188 whole-body fluorodeoxyglucose positron emission tomography scans in 137 patients with sarcoidosis.
Teirstein AS; Machac J; Almeida O; Lu P; Padilla ML; Iannuzzi MC
Chest; 2007 Dec; 132(6):1949-53. PubMed ID: 17925421
[TBL] [Abstract][Full Text] [Related]
5. Is there a role for fluorine 18 fluorodeoxyglucose-positron emission tomography and positron emission tomography/computed tomography in evaluating patients with mycobacteriosis? A systematic review.
Treglia G; Taralli S; Calcagni ML; Maggi F; Giordano A; Bonomo L
J Comput Assist Tomogr; 2011; 35(3):387-93. PubMed ID: 21586936
[TBL] [Abstract][Full Text] [Related]
6. The prognostic role of cardiac positron emission tomography imaging in patients with sarcoidosis: A systematic review.
Ahmed AI; Abebe AT; Han Y; Alnabelsi T; Agrawal T; Kassi M; Aljizeeri A; Taylor A; Tleyjeh IM; Al-Mallah MH
J Nucl Cardiol; 2021 Aug; 28(4):1545-1552. PubMed ID: 34228337
[TBL] [Abstract][Full Text] [Related]
7. Inflammatory activity assessment by F18 FDG-PET/CT in persistent symptomatic sarcoidosis.
Mostard RL; Vöö S; van Kroonenburgh MJ; Verschakelen JA; Wijnen PA; Nelemans PJ; Erckens RJ; Drent M
Respir Med; 2011 Dec; 105(12):1917-24. PubMed ID: 21899998
[TBL] [Abstract][Full Text] [Related]
8. Prospective Comparison of 99mTc-MDP Scintigraphy, Combined 18F-NaF and 18F-FDG PET/CT, and Whole-Body MRI in Patients with Breast and Prostate Cancer.
Minamimoto R; Loening A; Jamali M; Barkhodari A; Mosci C; Jackson T; Obara P; Taviani V; Gambhir SS; Vasanawala S; Iagaru A
J Nucl Med; 2015 Dec; 56(12):1862-8. PubMed ID: 26405167
[TBL] [Abstract][Full Text] [Related]
9. Usefulness of whole-body fluorine-18-fluorodeoxyglucose positron emission tomography in patients with large-vessel vasculitis: a systematic review.
Treglia G; Mattoli MV; Leccisotti L; Ferraccioli G; Giordano A
Clin Rheumatol; 2011 Oct; 30(10):1265-75. PubMed ID: 21833685
[TBL] [Abstract][Full Text] [Related]
10. Comparison of 18F-FDG and 67Ga-citrate in sarcoidosis imaging.
Prager E; Wehrschuetz M; Bisail B; Woltsche M; Schwarz T; Lanz H; Sorantin E; Aigner RM
Nuklearmedizin; 2008; 47(1):18-23. PubMed ID: 18278208
[TBL] [Abstract][Full Text] [Related]
11. FDG PET imaging in sarcoidosis.
Sobic-Saranovic D; Artiko V; Obradovic V
Semin Nucl Med; 2013 Nov; 43(6):404-11. PubMed ID: 24094707
[TBL] [Abstract][Full Text] [Related]
12. Intraocular sarcoidosis: association of clinical characteristics of uveitis with findings from 18F-labelled fluorodeoxyglucose positron emission tomography.
Rahmi A; Deshayes E; Maucort-Boulch D; Varron L; Grange JD; Kodjikian L; Seve P
Br J Ophthalmol; 2012 Jan; 96(1):99-103. PubMed ID: 21464036
[TBL] [Abstract][Full Text] [Related]
13. [Contingent diagnosis of sarcoidosis by 18F-fluorodeoxyglucose-positron emission tomography (FDG-PET) after completion of chemotherapy for malignant lymphoma].
Iino M; Iizuka C
Rinsho Ketsueki; 2012 May; 53(5):540-2. PubMed ID: 22728558
[TBL] [Abstract][Full Text] [Related]
14. 18F-FDG PET as a predictor of pulmonary function in sarcoidosis.
Keijsers RG; Verzijlbergen EJ; van den Bosch JM; Zanen P; van de Garde EM; Oyen WJ; Grutters JC
Sarcoidosis Vasc Diffuse Lung Dis; 2011 Oct; 28(2):123-9. PubMed ID: 22117503
[TBL] [Abstract][Full Text] [Related]
15. Prognostic Impact of Extent, Severity, and Heterogeneity of Abnormalities on
Sperry BW; Tamarappoo BK; Oldan JD; Javed O; Culver DA; Brunken R; Cerqueira MD; Hachamovitch R
JACC Cardiovasc Imaging; 2018 Feb; 11(2 Pt 2):336-345. PubMed ID: 28823747
[TBL] [Abstract][Full Text] [Related]
16. Diagnostic usefulness of fluorine-18-alpha-methyltyrosine positron emission tomography in combination with 18F-fluorodeoxyglucose in sarcoidosis patients.
Kaira K; Oriuchi N; Otani Y; Yanagitani N; Sunaga N; Hisada T; Ishizuka T; Endo K; Mori M
Chest; 2007 Apr; 131(4):1019-27. PubMed ID: 17426205
[TBL] [Abstract][Full Text] [Related]
17. Impact of [18F]-fluorodeoxyglucose ([18F]-FDG) imaging in sarcoidosis: unsuspected neurosarcoidosis discovered by [18F]-FDG PET and early metabolic response to corticosteroid therapy.
Aide N; Benayoun M; Kerrou K; Khalil A; Cadranel J; Talbot JN
Br J Radiol; 2007 Mar; 80(951):e67-71. PubMed ID: 17548505
[TBL] [Abstract][Full Text] [Related]
18. Nuclear medicine imaging in tuberculosis using commercially available radiopharmaceuticals.
Sathekge M; Maes A; D'Asseler Y; Vorster M; Van de Wiele C
Nucl Med Commun; 2012 Jun; 33(6):581-90. PubMed ID: 22422098
[TBL] [Abstract][Full Text] [Related]
19. The utility of 18F-FDG PET/CT for diagnosis and adjustment of therapy in patients with active chronic sarcoidosis.
Sobic-Saranovic D; Grozdic I; Videnovic-Ivanov J; Vucinic-Mihailovic V; Artiko V; Saranovic D; Djuric-Stefanovic A; Masulovic D; Odalovic S; Ilic-Dudvarski A; Popevic S; Pavlovic S; Obradovic V
J Nucl Med; 2012 Oct; 53(10):1543-9. PubMed ID: 22879080
[TBL] [Abstract][Full Text] [Related]
20. Feasibility of
Osiecki S; Sterliński M; Marciniak-Emmons M; Dziuk M
Int J Cardiovasc Imaging; 2021 Mar; 37(3):1097-1104. PubMed ID: 33063243
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
